Skip to main content
Top
Published in: BMC Medicine 1/2021

01-12-2021 | Breast Cancer | Commentary

Glucocorticoids and breast cancer risk

Authors: Kelly A. Hirko, A. Heather Eliassen

Published in: BMC Medicine | Issue 1/2021

Login to get access

Excerpt

Glucocorticoids are essential endogenous steroid hormones secreted in response to stress, and treatment with synthetic forms is widespread for numerous inflammatory conditions including asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, and arthritis [1]. Emerging evidence suggests that glucocorticoids can exert both anti- and pro-inflammatory effects, modulated through suppressing or augmenting immune response [1]. Given these divergent biologic properties, glucocorticoids could theoretically reduce breast cancer risk via anti-inflammatory effects or could increase breast cancer risk and progression by inducing insulin resistance and promoting immunosuppression [2]. Yet, despite biological plausibility, epidemiologic studies of glucocorticoid use and breast cancer are limited. …
Literature
3.
go back to reference Cairat M, Al Rahmoun M, Gunter MJ, et al. Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women (in press). BMC Med. 2021. Cairat M, Al Rahmoun M, Gunter MJ, et al. Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women (in press). BMC Med. 2021.
Metadata
Title
Glucocorticoids and breast cancer risk
Authors
Kelly A. Hirko
A. Heather Eliassen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2021
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-021-02036-y

Other articles of this Issue 1/2021

BMC Medicine 1/2021 Go to the issue